Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Completed · Phase 2 · Has a placebo group

Conditions studied: Pruritus, Notalgia Paresthetica

In brief

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with notalgia paresthetica and moderate to severe pruritus.

Key facts

Study ID
NCT04706975
Run by
Cara Therapeutics, Inc.
People needed
126
Starts
2021-01-11
Expected to finish
2022-06-30
Last updated by the study team
2023-05-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.